Single-point mutations within the kinase domain of BCR–ABL constitute the most frequent cause of acquired resistance to ABL kinase inhibitors in patients with chronic myeloid leukaemia (CML) receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results